Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1994 1
1995 1
1996 2
1997 2
1998 1
1999 1
2002 1
2003 1
2006 1
2008 1
2009 1
2012 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Kinin antagonists.
Cheronis JC, Whalley ET. Cheronis JC, et al. Lancet. 1991 Oct 19;338(8773):1011. doi: 10.1016/0140-6736(91)91868-u. Lancet. 1991. PMID: 1681311 No abstract available.
A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.
McConeghy KW, Hatton J, Hughes L, Cook AM. McConeghy KW, et al. CNS Drugs. 2012 Jul 1;26(7):613-36. doi: 10.2165/11634020-000000000-00000. CNS Drugs. 2012. PMID: 22668124 Review.
Many agents such as selfotel, pegorgotein (PEG-SOD), magnesium, deltibant and dexanabinol were ineffective in clinical trials. While progesterone and ciclosporin have shown promise in phase II studies, success in larger phase III, randomized, multicentre, clinical trials i …
Many agents such as selfotel, pegorgotein (PEG-SOD), magnesium, deltibant and dexanabinol were ineffective in clinical trials. While …
Angiotensin, bradykinin and the endothelium.
Dimitropoulou C, Chatterjee A, McCloud L, Yetik-Anacak G, Catravas JD. Dimitropoulou C, et al. Handb Exp Pharmacol. 2006;(176 Pt 1):255-94. doi: 10.1007/3-540-32967-6_8. Handb Exp Pharmacol. 2006. PMID: 16999222 Review.
Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group.
Fein AM, Bernard GR, Criner GJ, Fletcher EC, Good JT Jr, Knaus WA, Levy H, Matuschak GM, Shanies HM, Taylor RW, Rodell TC. Fein AM, et al. JAMA. 1997 Feb 12;277(6):482-7. JAMA. 1997. PMID: 9020273 Clinical Trial.
OBJECTIVE: To test the effect of a novel bradykinin antagonist, deltibant (CP-0127), on survival, organ dysfunction, and other outcomes in patients with the systemic inflammatory response syndrome (SIRS) and presumed sepsis. ...Risk adjustment was performed using a study-s …
OBJECTIVE: To test the effect of a novel bradykinin antagonist, deltibant (CP-0127), on survival, organ dysfunction, and other outcom …
16 results